Human Cancer Drug Targets PCR Array
The Human Cancer Drug Targets RT² Profiler™ PCR Array profiles the expression of 84 actively sought targets for anticancer therapeutics and drug development. Cancer is a heterogeneous disease with a variety of survival mechanisms resulting from accumulated mutations that alter gene expression. In one of its key roles, cancer research continually identifies novel dysregulated carcinogenesis-related genes elucidating new mechanisms of cancer progression or treatment evasion, and potentially leading to new avenues for drug development. Further research into the expression of these genes may identify how and when they are dysregulated and potentially discover the underlying mechanism(s) behind cancer growth and progression. This array includes genes dysregulated during carcinogenesis, including those involved in key cellular growth pathways such as apoptosis, DNA damage repair, epigenetics, and growth factor and other signaling pathways. Using real-time PCR, your research study can easily and reliably analyze the expression of a focused panel of genes involved in oncogenesis with this array.
Apoptosis: BCL2, BIRC5.
PI-3 Kinases & Phosphatases: MTOR, PIK3C2A, PIK3C3, PIK3CA.
Growth Factors & Receptors: EGFR, ERBB2, ERBB3, ERBB4, FIGF, FLT1, FLT4, IGF1, IGF1R, IGF2, KDR, KIT,PDGFRA, PDGFRB.
Drug Metabolism: ABCC1, GSTP1, PTGS2, TXN, TXNRD1.
G Protein Signaling: RHOA, RHOB.
Hormone Receptors: ESR1, ESR2, PGR.
Heat Shock Proteins: HSP90AA1, HSP90B1.
Receptor Tyrosine Kinase Signaling: AKT1, AKT2, GRB2.
Cathepsins: CTSB, CTSD, CTSL1, CTSS.
Cell Cycle: CDK1, CDC25A, CDK2, CDK4, CDK5, CDK7, CDK8, CDK9, MDM2, MDM4, TERT.
Topoisomerases, Type II: TOP2A, TOP2B.
Transcription Factors: ATF2, HIF1A, IRF5, NFKB1, TP53.
Protein Kinases: AURKA, AURKB, AURKC, PLK1, PLK2, PLK3, PLK4, PRKCA, PRKCB, PRKCD, PRKCE.
RAS Signaling: HRAS, KRAS, NRAS.
Histone Deacetylases: HDAC1, HDAC11, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8.
Poly ADP-Ribose Polymerases: PARP1, PARP2, PARP4, TNKS.
Structural Protein: NTN3.